These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25896474)

  • 21. Subjective health expectations at biological therapy initiation: a survey of rheumatoid arthritis patients and rheumatologists.
    Péntek M; Gulácsi L; Rojkovich B; Brodszky V; van Exel J; Brouwer WB
    Eur J Health Econ; 2014 May; 15 Suppl 1():S83-92. PubMed ID: 24832839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural damages disturb functional improvement in patients with rheumatoid arthritis treated with etanercept.
    Tanaka Y; Yamanaka H; Saito K; Iwata S; Miyagawa I; Seto Y; Momohara S; Nagasawa H; Kameda H; Kaneko Y; Izumi K; Amano K; Takeuchi T
    Mod Rheumatol; 2012 Apr; 22(2):186-94. PubMed ID: 21901357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activity.
    Tymms K; Zochling J; Scott J; Bird P; Burnet S; de Jager J; Griffiths H; Nicholls D; Roberts L; Arnold M; Littlejohn G
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):190-6. PubMed ID: 23983001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care?
    Pincus T
    Bull NYU Hosp Jt Dis; 2009; 67(3):254-66. PubMed ID: 19852747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
    Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
    J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data.
    Alemao E; Joo S; Kawabata H; Al MJ; Allison PD; Rutten-van Mölken MP; Frits ML; Iannaccone CK; Shadick NA; Weinblatt ME
    Arthritis Care Res (Hoboken); 2016 Mar; 68(3):308-17. PubMed ID: 26238974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease activity assessment of rheumatoid arthritis in daily practice: validity, internal consistency, reliability and congruency of the Disease Activity Score including 28 joints (DAS28) compared with the Clinical Disease Activity Index (CDAI).
    Salaffi F; Cimmino MA; Leardini G; Gasparini S; Grassi W
    Clin Exp Rheumatol; 2009; 27(4):552-9. PubMed ID: 19772784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.
    Saraux A; Benichou J; Guillevin L; Idbrik L; Job-Deslandre C; Sibilia J; Soudant M; Wendling D; Guillemin F
    Clin Exp Rheumatol; 2015; 33(5):602-10. PubMed ID: 26315585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort.
    Albrecht K; Callhoff J; Schneider M; Zink A
    Rheumatol Int; 2015 Aug; 35(8):1377-84. PubMed ID: 25663291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Health assessment questionnaire score is the best predictor of 5-year quality of life in early rheumatoid arthritis.
    Cohen JD; Dougados M; Goupille P; Cantagrel A; Meyer O; Sibilia J; Daurès JP; Combe B
    J Rheumatol; 2006 Oct; 33(10):1936-41. PubMed ID: 16924692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression.
    Brown AK; Quinn MA; Karim Z; Conaghan PG; Peterfy CG; Hensor E; Wakefield RJ; O'Connor PJ; Emery P
    Arthritis Rheum; 2006 Dec; 54(12):3761-73. PubMed ID: 17133543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis.
    Feuchtenberger M; Kleinert S; Scharbatke EC; Gnann H; Behrens F; Wittig BM; Greger G; Tony HP
    Clin Exp Rheumatol; 2015; 33(3):321-9. PubMed ID: 25897681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measuring functional disability in early rheumatoid arthritis: the validity, reliability and responsiveness of the Recent-Onset Arthritis Disability (ROAD) index.
    Salaffi F; Stancati A; Neri R; Grassi W; Bombardieri S
    Clin Exp Rheumatol; 2005; 23(5 Suppl 39):S31-42. PubMed ID: 16273783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rheumatoid atlantoaxial subluxation can be prevented by intensive use of traditional disease modifying antirheumatic drugs.
    Kauppi MJ; Neva MH; Laiho K; Kautiainen H; Luukkainen R; Karjalainen A; Hannonen PJ; Leirisalo-Repo M; Korpela M; Ilva K; Möttönen T;
    J Rheumatol; 2009 Feb; 36(2):273-8. PubMed ID: 19132793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort.
    Khanna D; Oh M; Furst DE; Ranganath V; Gold RH; Sharp JT; Park GS; Keystone EC; Paulus HE;
    Arthritis Rheum; 2007 Apr; 57(3):440-7. PubMed ID: 17394230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis.
    Thiele K; Huscher D; Bischoff S; Späthling-Mestekemper S; Backhaus M; Aringer M; Kohlmann T; Zink A;
    Ann Rheum Dis; 2013 Jul; 72(7):1194-9. PubMed ID: 22915625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
    Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
    Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.
    Vermeer M; Kuper HH; Moens HJ; Drossaers-Bakker KW; van der Bijl AE; van Riel PL; van de Laar MA
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1219-26. PubMed ID: 23436821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.